Zydus Lifesciences announced that its drug Desidustat, used to treat anaemia in chronic kidney disease (CKD) patients, received approval from China’s National Medical Products Administration. With over 120 million people affected by CKD in China, the approval marks a significant milestone. The drug, marketed as Oxemia in India, was licensed to China Medical System Holdings for development and commercialization in Greater China. Sharvil Patel, MD of Zydus Lifesciences, expressed optimism about empowering patients with the therapy.
Zydus Lifesciences Receives Approval for Anaemia Drug in China Amid Rising CKD Cases
![](https://affairsace-media.s3.ap-south-1.amazonaws.com/2024/04/26132220/1645698520-5301-ezgif.com-avif-to-jpg-converter.jpg)